Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
18.00
-0.50 (-2.70%)
At close: Feb 21, 2025, 4:00 PM
13.46
-4.54 (-25.22%)
After-hours: Feb 21, 2025, 7:57 PM EST
Axogen Revenue
Axogen had revenue of $48.64M in the quarter ending September 30, 2024, with 17.86% growth. This brings the company's revenue in the last twelve months to $180.86M, up 18.79% year-over-year. In the year 2023, Axogen had annual revenue of $159.01M with 14.74% growth.
Revenue (ttm)
$180.86M
Revenue Growth
+18.79%
P/S Ratio
4.33
Revenue / Employee
$422,558
Employees
428
Market Cap
792.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | 106.71M | 22.78M | 27.13% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AXGN News
- 10 days ago - Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 - GlobeNewsWire
- 6 weeks ago - Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Axogen: Well Placed To Capitalize Growth At Higher Multiples - Seeking Alpha
- 3 months ago - Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® - GlobeNewsWire
- 7 months ago - Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Axogen, Inc. Announces New Leadership Appointments - GlobeNewsWire
- 7 months ago - Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 - GlobeNewsWire